Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Rating) – Cantor Fitzgerald upped their FY2022 EPS estimates for Galmed Pharmaceuticals in a report released on Wednesday, May 18th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will earn ($0.56) per share for the year, up from their prior forecast of ($1.16).
Other research analysts have also issued reports about the company. Zacks Investment Research raised Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a report on Friday. HC Wainwright lowered Galmed Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, May 3rd. Canaccord Genuity Group decreased their target price on Galmed Pharmaceuticals from $24.00 to $5.00 in a research note on Wednesday, May 4th. StockNews.com began coverage on Galmed Pharmaceuticals in a research note on Saturday. They set a “sell” rating for the company. Finally, Raymond James cut Galmed Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 18th.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Rating) last issued its quarterly earnings results on Tuesday, May 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08.
Several large investors have recently added to or reduced their stakes in GLMD. Millennium Management LLC boosted its position in shares of Galmed Pharmaceuticals by 308.4% in the 4th quarter. Millennium Management LLC now owns 53,239 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 40,203 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of Galmed Pharmaceuticals by 158.9% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 63,310 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 38,856 shares during the period. Virtu Financial LLC acquired a new position in shares of Galmed Pharmaceuticals in the 4th quarter valued at $65,000. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Galmed Pharmaceuticals in the 1st quarter valued at $42,000. Finally, Toroso Investments LLC acquired a new position in shares of Galmed Pharmaceuticals in the 3rd quarter valued at $69,000. Institutional investors and hedge funds own 13.37% of the company’s stock.
About Galmed Pharmaceuticals (Get Rating)
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
- Get a free copy of the StockNews.com research report on Galmed Pharmaceuticals (GLMD)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.